Reviews Remicade


No reviews yet.

Remicade Drug Description

REMICADE
(infliximab) Lyophilized Concentrate for Intravenous (IV) Injection

WARNINGS
SERIOUS INFECTIONS
Patients treated with REMICADE® are at increased risk for developing
serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS] Most patients who developed these infections
were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
REMICADE should be discontinued if a patient develops a serious infection
or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients
with tuberculosis have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent tuberculosis before REMICADE
use and during therapy.1,2 Treatment for latent infection should
be initiated prior to REMICADE use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis,
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may present with disseminated,
rather than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric anti-fungal
therapy should be considered in patients at risk for invasive fungal infections
who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.


The risks and benefits of treatment with REMICADE should be carefully considered
prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms
of infection during and after treatment with REMICADE, including the possible
development of tuberculosis in patients who tested negative for latent tuberculosis
infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children
and adolescent patients treated with TNF blockers, including REMICADE [see WARNINGS AND PRECAUTIONS].
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type
of T-cell lymphoma, have been reported in patients treated with TNF blockers
including REMICADE. These cases have had a very aggressive disease course and
have been fatal. All reported REMICADE cases have occurred in patients with
Crohn's disease or ulcerative colitis and the majority were in adolescent and
young adult males. All of these patients had received treatment with azathioprine
or 6-mercaptopurine concomitantly with REMICADE at or prior to diagnosis.

DRUG DESCRIPTION



What are the possible side effects of infliximab (Remicade)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with infliximab. Stop using infliximab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore throat;
flu symptoms, weight...
Read All Potential Side Effects for Remicade »




Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal
antibody (composed of human constant and murine variable regions) specific for
human tumor necrosis factor-alpha (TNFα). It has a molecular weight of
approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell
line cultured by continuous perfusion and is purified by a series of steps that
includes measures to inactivate and remove viruses.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous
infusion. Following reconstitution with 10 mL of Sterile Water for Injection,
USP, the resulting pH is approximately 7.2. Each single-use vial contains 100
mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium
phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives
are present.
REFERENCES
1. American Thoracic Society, Centers for Disease Control and
Prevention. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations
for tuberculosis testing in immunocompromised patients.
Last reviewed on RxList: 8/31/2010




Remicade Drug Description

REMICADE
(infliximab) Lyophilized Concentrate for Intravenous (IV) Injection

WARNINGS
SERIOUS INFECTIONS
Patients treated with REMICADE® are at increased risk for developing
serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS] Most patients who developed these infections
were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
REMICADE should be discontinued if a patient develops a serious infection
or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients
with tuberculosis have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent tuberculosis before REMICADE
use and during therapy.1,2 Treatment for latent infection should
be initiated prior to REMICADE use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis,
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may present with disseminated,
rather than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric anti-fungal
therapy should be considered in patients at risk for invasive fungal infections
who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.


The risks and benefits of treatment with REMICADE should be carefully considered
prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms
of infection during and after treatment with REMICADE, including the possible
development of tuberculosis in patients who tested negative for latent tuberculosis
infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children
and adolescent patients treated with TNF blockers, including REMICADE [see WARNINGS AND PRECAUTIONS].
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type
of T-cell lymphoma, have been reported in patients treated with TNF blockers
including REMICADE. These cases have had a very aggressive disease course and
have been fatal. All reported REMICADE cases have occurred in patients with
Crohn's disease or ulcerative colitis and the majority were in adolescent and
young adult males. All of these patients had received treatment with azathioprine
or 6-mercaptopurine concomitantly with REMICADE at or prior to diagnosis.

DRUG DESCRIPTION



What are the possible side effects of infliximab (Remicade)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with infliximab. Stop using infliximab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore throat;
flu symptoms, weight...
Read All Potential Side Effects for Remicade »




Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal
antibody (composed of human constant and murine variable regions) specific for
human tumor necrosis factor-alpha (TNFα). It has a molecular weight of
approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell
line cultured by continuous perfusion and is purified by a series of steps that
includes measures to inactivate and remove viruses.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous
infusion. Following reconstitution with 10 mL of Sterile Water for Injection,
USP, the resulting pH is approximately 7.2. Each single-use vial contains 100
mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium
phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives
are present.
REFERENCES
1. American Thoracic Society, Centers for Disease Control and
Prevention. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations
for tuberculosis testing in immunocompromised patients.
Last reviewed on RxList: 8/31/2010




Remicade Drug Description

REMICADE
(infliximab) Lyophilized Concentrate for Intravenous (IV) Injection

WARNINGS
SERIOUS INFECTIONS
Patients treated with REMICADE® are at increased risk for developing
serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS] Most patients who developed these infections
were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
REMICADE should be discontinued if a patient develops a serious infection
or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients
with tuberculosis have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent tuberculosis before REMICADE
use and during therapy.1,2 Treatment for latent infection should
be initiated prior to REMICADE use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis,
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may present with disseminated,
rather than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric anti-fungal
therapy should be considered in patients at risk for invasive fungal infections
who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.


The risks and benefits of treatment with REMICADE should be carefully considered
prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms
of infection during and after treatment with REMICADE, including the possible
development of tuberculosis in patients who tested negative for latent tuberculosis
infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children
and adolescent patients treated with TNF blockers, including REMICADE [see WARNINGS AND PRECAUTIONS].
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type
of T-cell lymphoma, have been reported in patients treated with TNF blockers
including REMICADE. These cases have had a very aggressive disease course and
have been fatal. All reported REMICADE cases have occurred in patients with
Crohn's disease or ulcerative colitis and the majority were in adolescent and
young adult males. All of these patients had received treatment with azathioprine
or 6-mercaptopurine concomitantly with REMICADE at or prior to diagnosis.

DRUG DESCRIPTION



What are the possible side effects of infliximab (Remicade)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with infliximab. Stop using infliximab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore throat;
flu symptoms, weight...
Read All Potential Side Effects for Remicade »




Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal
antibody (composed of human constant and murine variable regions) specific for
human tumor necrosis factor-alpha (TNFα). It has a molecular weight of
approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell
line cultured by continuous perfusion and is purified by a series of steps that
includes measures to inactivate and remove viruses.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous
infusion. Following reconstitution with 10 mL of Sterile Water for Injection,
USP, the resulting pH is approximately 7.2. Each single-use vial contains 100
mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium
phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives
are present.
REFERENCES
1. American Thoracic Society, Centers for Disease Control and
Prevention. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations
for tuberculosis testing in immunocompromised patients.
Last reviewed on RxList: 8/31/2010




Remicade Drug Description

REMICADE
(infliximab) Lyophilized Concentrate for Intravenous (IV) Injection

WARNINGS
SERIOUS INFECTIONS
Patients treated with REMICADE® are at increased risk for developing
serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS] Most patients who developed these infections
were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
REMICADE should be discontinued if a patient develops a serious infection
or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients
with tuberculosis have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent tuberculosis before REMICADE
use and during therapy.1,2 Treatment for latent infection should
be initiated prior to REMICADE use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis,
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may present with disseminated,
rather than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric anti-fungal
therapy should be considered in patients at risk for invasive fungal infections
who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.


The risks and benefits of treatment with REMICADE should be carefully considered
prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms
of infection during and after treatment with REMICADE, including the possible
development of tuberculosis in patients who tested negative for latent tuberculosis
infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children
and adolescent patients treated with TNF blockers, including REMICADE [see WARNINGS AND PRECAUTIONS].
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type
of T-cell lymphoma, have been reported in patients treated with TNF blockers
including REMICADE. These cases have had a very aggressive disease course and
have been fatal. All reported REMICADE cases have occurred in patients with
Crohn's disease or ulcerative colitis and the majority were in adolescent and
young adult males. All of these patients had received treatment with azathioprine
or 6-mercaptopurine concomitantly with REMICADE at or prior to diagnosis.

DRUG DESCRIPTION



What are the possible side effects of infliximab (Remicade)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with infliximab. Stop using infliximab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore throat;
flu symptoms, weight...
Read All Potential Side Effects for Remicade »




Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal
antibody (composed of human constant and murine variable regions) specific for
human tumor necrosis factor-alpha (TNFα). It has a molecular weight of
approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell
line cultured by continuous perfusion and is purified by a series of steps that
includes measures to inactivate and remove viruses.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous
infusion. Following reconstitution with 10 mL of Sterile Water for Injection,
USP, the resulting pH is approximately 7.2. Each single-use vial contains 100
mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium
phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives
are present.
REFERENCES
1. American Thoracic Society, Centers for Disease Control and
Prevention. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations
for tuberculosis testing in immunocompromised patients.
Last reviewed on RxList: 8/31/2010




Remicade Drug Description

REMICADE
(infliximab) Lyophilized Concentrate for Intravenous (IV) Injection

WARNINGS
SERIOUS INFECTIONS
Patients treated with REMICADE® are at increased risk for developing
serious infections that may lead to hospitalization or death [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS] Most patients who developed these infections
were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
REMICADE should be discontinued if a patient develops a serious infection
or sepsis.
Reported infections include:

Active tuberculosis, including reactivation of latent tuberculosis. Patients
with tuberculosis have frequently presented with disseminated or extrapulmonary
disease. Patients should be tested for latent tuberculosis before REMICADE
use and during therapy.1,2 Treatment for latent infection should
be initiated prior to REMICADE use.
Invasive fungal infections, including histoplasmosis, coccidioidomycosis,
candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with
histoplasmosis or other invasive fungal infections may present with disseminated,
rather than localized, disease. Antigen and antibody testing for histoplasmosis
may be negative in some patients with active infection. Empiric anti-fungal
therapy should be considered in patients at risk for invasive fungal infections
who develop severe systemic illness.
Bacterial, viral and other infections due to opportunistic pathogens.


The risks and benefits of treatment with REMICADE should be carefully considered
prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms
of infection during and after treatment with REMICADE, including the possible
development of tuberculosis in patients who tested negative for latent tuberculosis
infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children
and adolescent patients treated with TNF blockers, including REMICADE [see WARNINGS AND PRECAUTIONS].
Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type
of T-cell lymphoma, have been reported in patients treated with TNF blockers
including REMICADE. These cases have had a very aggressive disease course and
have been fatal. All reported REMICADE cases have occurred in patients with
Crohn's disease or ulcerative colitis and the majority were in adolescent and
young adult males. All of these patients had received treatment with azathioprine
or 6-mercaptopurine concomitantly with REMICADE at or prior to diagnosis.

DRUG DESCRIPTION



What are the possible side effects of infliximab (Remicade)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Serious and sometimes fatal infections may occur during treatment with infliximab. Stop using infliximab and call your doctor right away if you have signs of infection such as:

fever, sweating, chills, tired feeling;
feeling short of breath;
cough, sore throat;
flu symptoms, weight...
Read All Potential Side Effects for Remicade »




Infliximab, the active ingredient in REMICADE, is a chimeric IgG1κ monoclonal
antibody (composed of human constant and murine variable regions) specific for
human tumor necrosis factor-alpha (TNFα). It has a molecular weight of
approximately 149.1 kilodaltons. Infliximab is produced by a recombinant cell
line cultured by continuous perfusion and is purified by a series of steps that
includes measures to inactivate and remove viruses.
REMICADE is supplied as a sterile, white, lyophilized powder for intravenous
infusion. Following reconstitution with 10 mL of Sterile Water for Injection,
USP, the resulting pH is approximately 7.2. Each single-use vial contains 100
mg infliximab, 500 mg sucrose, 0.5 mg polysorbate 80, 2.2 mg monobasic sodium
phosphate, monohydrate, and 6.1 mg dibasic sodium phosphate, dihydrate. No preservatives
are present.
REFERENCES
1. American Thoracic Society, Centers for Disease Control and
Prevention. Targeted tuberculin testing and treatment of latent tuberculosis
infection. Am J Respir Crit Care Med 2000;161:S221-S247.
2. See latest Centers for Disease Control guidelines and recommendations
for tuberculosis testing in immunocompromised patients.
Last reviewed on RxList: 8/31/2010





Other reviews about Remicade on wordpress

Is the Merck/Schering merger going to run into legal problems?
  by silico
David Feldman, of Feldman Weinstein & Smith LLP, is a lawyer who specialises in reverse mergers. A reverse merger is one in which a private company becomes publicly […]


Schering-Plough Expects a Challenge -- on Remicade -- from JNJ
  by condor
Yep -- that may plainly be inferred from Schering-Plough's latest Rule 425 prospectus material filed yesterday afternoon with the SEC -- the shiny-new SMIRK (Heh!) filed a Q&A […]


Dueling Patent Suits -- Involving Remicadeツョ and Now, Simponiツョ. . . .
  by condor
In early 2007, in the federal courts in the Eastern District of Texas, Centocor sued Abbott for patent infringement -- alleging that Abbott's Humiraツョ (adalimumab), infringed […]


Johnson & Johnson goes to arbitration to end Remicade partnership with Schering-Plough
  by silico
AP is reporting that Johnson & Johnson has notified Merck & Co. that it plans to seek arbitration on whether it can pull out of its Remicade partnership […]


Nadia's Remicade Infusion
  by Dennis
Our friend Nadia has a new set of videos up about her recent trip to get a Remicade infusion. For those who have never been on Remicade, her […]


Rae's Intro to Crohn's Disease
  by Dennis
A 20-something girl with Crohn's disease, Rae, shares about her life with IBD. She reads some poetry she's written and tells us what she's gone through. Check out […]


St. Cloud
  by Angela
I'm driving up to St. Cloud tomorrow morning (EARLY! auuugh...6:30) to take photos for the Arthritis Foundation. ツThere's an arthritis fundraising walk going on there, similar to the […]


Remicade...really a remedy?
  by emilykaty
Today is my first infusion of remicade. I am scared to death.I am told the IV procedure takes 3 hours to administer. I have been off of Humira(which […]


I want to jump out of my skin.
  by emilykaty
After another set of false hopes and dreams is crushed...I am on the recovery and mend from yet another allergic reaction. Who would have guessed? I knew it. […]


Remicade (infliximab)
  by Angela
[caption id="attachment_153" align="alignleft" width="247" caption="More terrifying - the needle or me with no makeup?"][/caption] I had my Remicade I.V. infusion today which went well, as usual. ツToday's session was […]



Other reviews about Remicade on web:

Learn about REMICADEテδεつッテδづつソテδづつス (infliximab), a breakthrough biologic that has helped to treat various inflammatory disorders. REMICADEテδづつョ (infliximab) Biologic Treatment


Infliximab (INN; trade name Remicade) is a monoclonal antibody against TNFテδ偲つア. It is used to treat autoimmune diseases. Remicade is marketed by Centocor Ortho Biotech (Centocor) in the ... Infliximab - Wikipedia, the free encyclopedia


Remicade (infliximab) is used to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn's disease. Includes Remicade side effects, interactions and ... Remicade (infliximab) Information from Drugs.com


REMICADEテδεつッテδづつソテδづつス (infliximab) has been proven to reduce the signs and symptoms of Crohn's disease and is the is the first and only treatment approved for moderate to severe Crohn ... Remicade


Learn about the prescription medication Remicade (Infliximab), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Remicade (Infliximab) Drug Information: Uses, Side Effects, Drug ...


Accurate, FDA approved Remicade information for healthcare professionals and patients - brought to you by Drugs.com. Remicade Official FDA information, side effects and uses.


Remicade is a monoclonal antibody used along with methotrexate to reduce inflammation and other symptoms associated with moderate to severe rheumatoid arthritis. Side effects and ... Remicade - drugstore.com. Low prices, side effects, interactions.


Remicade is a prescription medication that is approved to treat certain inflammatory conditions. This eMedTV page explains how the drug works to relieve symptoms of these ... Remicade


Infliximab (brand name Remicade&trade) is a powerful drug used to treat auto-immune disorders like Crohn\'s disease, ulcerative colitis and ... Remicade: 773 user reviews - DailyStrength


remicade: noun: 1. a monoclonal antibody (trade name Remicade) used to treat Crohn's disease and rheumatoid arthritis; administered by infusion; use and dosage must be determined by a ... Remicade | Define Remicade at Dictionary.com





Featured Reviews

Reviews Activase

Activase Drug Description ACTIVASE® (alteplase) A Recombinant Tissue Plasminogen Activator DRUG DESCRIPTION Activase® (Alteplase) is a tissue plasminogen activator produced by recombinant DNA technology. It is a sterile, purified...
Read More  |  Review This
Reviews Anzemet Tablets

Anzemet Tablets Drug Description ANZEMET® (dolasetron mesylate) Tablets DRUG DESCRIPTION What are the possible side effects of dolasetron (Anzemet)? If you experience any of the following uncommon but serious side effects,...
Read More  |  Review This
Reviews Antihemophilic Factor

Recombinate Drug Description RECOMBINATE Antihemophilic Factor (Recombinant) DRUG DESCRIPTION RECOMBINATE, Antihemophilic Factor (Recombinant) (rAHF) is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary (CHO)...
Read More  |  Review This
Reviews Protonix I.V.

Protonix I.V. Drug Description PROTONIX® I.V. (pantoprazole sodium) for Injection DRUG DESCRIPTION The active ingredient in PROTONIX® I.V. (pantoprazole sodium) for Injection is a substituted benzimidazole, sodium 5-(difluoromethoxy)-2-[[...
Read More  |  Review This
Reviews Pioglitazone Hydrochloride and Glimepiride Tablets

Duetact Drug Description DUETACT® (pioglitazone hydrochloride and glimepiride) Tablets WARNING CONGESTIVE HEART FAILURE Thiazolidinediones, including pioglitazone, which is a component of DUETACT, cause or exacerbate congestive...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....